Lacey Johnson1, Denese Marks1. 1. Research and Development, Australian Red Cross Blood Service, Sydney, NSW, Australia.
Abstract
BACKGROUND: Pathogen inactivation (PI) technologies for platelets aim to improve transfusion safety by preventing the replication of contaminating pathogens. However, as a consequence of treatment, aspects of the platelet storage lesion are amplified. Mirasol treatment also affects platelet signal transduction and apoptotic protein expression. The aim of this study was to examine the effect of Mirasol treatment on the generation of reactive oxygen species (ROS) and subsequent oxidative stress. METHODS: Pooled platelet concentrates were prepared in platelet-additive solution (70% SSP+ / 30% plasma). ABO-matched platelets were pooled and split, and treated with the Mirasol system (TerumoBCT) or left untreated as a control. Platelet samples were tested on day 1, 5, and 7 post-collection. RESULTS: Mirasol-treated platelets had increased formation of ROS by day 5 of storage. Oxidative damage, in the form of protein carbonylation, was higher in Mirasol-treated platelets, whilst no effect on nitrotyrosine formation or lipid peroxidation was detected. The NF-κB signaling pathway was also activated in Mirasol-treated platelets, with increased expression and phosphorylation of NF-κB p65 and IκBα. CONCLUSION: These data demonstrate that Mirasol-treated platelets produce more ROS and display protein alterations consistent with oxidative damage.
BACKGROUND: Pathogen inactivation (PI) technologies for platelets aim to improve transfusion safety by preventing the replication of contaminating pathogens. However, as a consequence of treatment, aspects of the platelet storage lesion are amplified. Mirasol treatment also affects platelet signal transduction and apoptotic protein expression. The aim of this study was to examine the effect of Mirasol treatment on the generation of reactive oxygen species (ROS) and subsequent oxidative stress. METHODS: Pooled platelet concentrates were prepared in platelet-additive solution (70% SSP+ / 30% plasma). ABO-matched platelets were pooled and split, and treated with the Mirasol system (TerumoBCT) or left untreated as a control. Platelet samples were tested on day 1, 5, and 7 post-collection. RESULTS: Mirasol-treated platelets had increased formation of ROS by day 5 of storage. Oxidative damage, in the form of protein carbonylation, was higher in Mirasol-treated platelets, whilst no effect on nitrotyrosine formation or lipid peroxidation was detected. The NF-κB signaling pathway was also activated in Mirasol-treated platelets, with increased expression and phosphorylation of NF-κB p65 and IκBα. CONCLUSION: These data demonstrate that Mirasol-treated platelets produce more ROS and display protein alterations consistent with oxidative damage.
Authors: Sisse R Ostrowski; Louise Bochsen; José A Salado-Jimena; Henrik Ullum; Inge Reynaerts; Raymond P Goodrich; Pär I Johansson Journal: Transfusion Date: 2010-10-04 Impact factor: 3.157
Authors: Sisse R Ostrowski; Louise Bochsen; Nis A Windeløv; José A Salado-Jimena; Inge Reynaerts; Raymond P Goodrich; Pär I Johansson Journal: Transfusion Date: 2010-08-16 Impact factor: 3.157
Authors: E Malaver; M A Romaniuk; L P D'Atri; R G Pozner; S Negrotto; R Benzadón; M Schattner Journal: J Thromb Haemost Date: 2009-06-03 Impact factor: 5.824
Authors: Lacey Johnson; Kelly M Winter; Tanja Hartkopf-Theis; Samantha Reid; Matthew Kwok; Denese C Marks Journal: Transfusion Date: 2011-08-31 Impact factor: 3.157
Authors: María P Montaña; Walter A Massad; Susana Criado; Alicia Biasutti; Norman A García Journal: Photochem Photobiol Date: 2010-06-07 Impact factor: 3.421
Authors: Peter Schubert; Brankica Culibrk; Danielle Coupland; Ken Scammell; Maria Gyongyossy-Issa; Dana V Devine Journal: Transfusion Date: 2011-08-09 Impact factor: 3.157
Authors: Geraldine M Walsh; Andrew W Shih; Ziad Solh; Mia Golder; Peter Schubert; Margaret Fearon; William P Sheffield Journal: Transfus Med Rev Date: 2016-02-23